2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Cell Expansion, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Women’s Health, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bone Marrow Failure Syndromes, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

4278 Declining non-relapse mortality drives improved long-term survival after allo-HSCT in pediatric RUNX1::RUNX1T1–Positive AML: A 10-year, 239-patient cohort study

Mingnan Zhang, Jiarui Zhou2, Min Xiong3, Xingyu Cao, MD4, Jian-Ping Zhang5, Yue Lu, PhD6, Zhijie Wei, MD7, Deyan Liu8, Yanli Zhao9, Peihua (Peggy) Lu, MD10, Ruijuan Sun, MD11
1 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
2 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
3 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
4 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
5 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
6 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
7 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
8 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
9 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
10 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
11 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China

Background

RUNX1::RUNX1T1-positive acute myeloid leukemia (AML) is traditionally considered a favorable-risk subtype; however, patients with high-risk features, including measurable residual disease (MRD), KIT mutations, or relapsed/refractory disease, remain at substantial risk of treatment failure. The impact of contemporary allogeneic hematopoietic stem cell transplantation (allo-HSCT) and factors driving long-term survival in this population remain poorly defined.

Methods

We retrospectively analyzed pediatric patients (aged 0–17 years) with high-risk RUNX1::RUNX1T1-positive AML who underwent allo-HSCT at Hebei Yanda Ludaopei Hospital between 2015 and 2024. Clinical outcomes were evaluated from transplantation, including overall survival (OS), disease-free survival (DFS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM). Survival outcomes were estimated using Kaplan-Meier analysis, relapse and NRM were evaluated using competing-risk methods, and outcomes were compared between two transplant eras (2015–2019 vs 2020–2024). Multivariable Cox regression and time-dependent analyses were performed to identify prognostic factors.

Results

A total of 239 patients were included, with a median follow-up of 62.2 months. The median age at transplantation was 10 years. This cohort represented a high-risk population, including 143 patients (59.8%) with pre-HSCT MRD positivity, 64 (26.8%) transplanted beyond CR1, and 32 (13.4%) transplanted with non-remission disease. Haploidentical donors were used in 203 patients (84.9%).

For the entire cohort, the 5-year OS and DFS were 76.9% (95% CI, 70.9–81.8) and 72.4% (95% CI, 66.2–77.7), respectively. Disease control was excellent, with a 5-year CIR of 5.1% (95% CI, 2.8–8.5). The 5-year NRM was 17.9% (95% CI, 13.3–23.1). The cumulative incidences of grade III–IV acute GVHD, chronic GVHD, and TA-TMA were 20.5%, 45.6%, and 3.8%, respectively.

Patients transplanted during 2020–2024 (n=122) and 2015–2019 (n=117) had comparable baseline characteristics and transplant features. Compared with the earlier era, the recent era demonstrated significantly improved 5-year OS (83.4% vs 70.8%) and DFS (77.8% vs 67.4%). This survival improvement was not attributable to reduced relapse, as CIR remained consistently low (4.3% vs 6.0%), but was primarily driven by a marked reduction in NRM (12.4% vs 23.2%). Correspondingly, severe transplant-related complications declined, including grade III–IV acute GVHD (18.0% vs 23.1%), chronic GVHD (42.1% vs 48.9%), and TA-TMA (2.5% vs 5.1%).

 In multivariable analysis, post-HSCT MRD positivity was independently associated with inferior overall survival (HR, 3.94; 95% CI, 2.14–6.99; P<0.0001). Time-dependent analyses demonstrated that grade III–IV acute GVHD was strongly associated with increased mortality (HR, 3.21; 95% CI, 1.84–5.52; P<0.0001) and non-relapse mortality (HR, 4.82; 95% CI, 2.56–9.08; P<0.0001), while TA-TMA was also associated with inferior survival (HR, 3.50; 95% CI, 1.18–8.43; P=0.0108).

Conclusion

Allo-HSCT achieved durable disease control and long-term survival in high-risk pediatric RUNX1::RUNX1T1-positive AML, with a 5-year relapse incidence of only 5.1%. Survival improvement over the past decade was primarily driven by reduced transplant-related mortality rather than further reduction in relapse. Continued optimization of GVHD prevention, TA-TMA management, and supportive transplant strategies represents the key pathway to further improve outcomes in this population.

Mingnan Zhang: No relevant conflicts of interest to declare.